Biotech IV Monitor

AGIO — Agios Pharmaceuticals Inc.

$2.2B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Agios Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2029.

Next readoutMarch 2029in ~28 months
Upcoming readouts44 Phase 3
Market cap$2.2B
Cash & investments$1.18B~18 quarters at last loss rate
Recent 8-K filings1latest 2026-11-05

Upcoming readouts

Phase 3 Mitapivat
Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia · NCT07517133
March 2029
Recruiting
Phase 3 Mitapivat Matched Placebo
Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia · NCT07506863
June 2029
Recruiting
Phase 3 Mitapivat Matched Placebo
Sickle Cell Disease · NCT07656415
August 2029
Recruiting
Phase 2/3 AG-236
Polycythemia Vera · NCT07859423
August 2030
Not Yet Recruiting

Cash position

Agios Pharmaceuticals Inc. reported $1.18B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $65M; at that rate the cash would last about 18 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05

Companies working on similar indications

Discussion

No messages yet. If you follow AGIO, you can start the conversation.
Track AGIO in real time
See live implied volatility for AGIO and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on AGIO
Contact — questions or corrections about AGIO: dukeupt@gmail.com